-transparent.png){kind=logo}
Sixty-three newly admitted schizophrenic patients were given a test dose of thiothixene and their subjective response was recorded by a technician blind to clinical ratings. All patients were then treated wih thiothixene in an active milieu setting. Patients varied widely in their subjective responses. An initial dysphoric response was a powerful predictor of both immediate and eventual drug refusal. Before treatment, dysphoric responders tended to be less symptomatic and did significantly better on the Continuous Performance Test. Dysphoric responders experienced significantly more extrapyramidal symptoms following the test dose. Some dysphoric responders did have a good outcome when treated with very low doses. We recommend that patients with a history of dysphoric response be given a very low dose initially.
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
April 1984,
Journal of clinical psychopharmacology,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
December 2005,
Journal of clinical psychopharmacology,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
March 2012,
Psychiatry investigation,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
May 2001,
Schizophrenia research,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
January 1978,
Psychopharmacology bulletin,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
January 2008,
Epidemiologia e psichiatria sociale,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
January 1999,
Psychopharmacology,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
February 1998,
The American journal of psychiatry,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
April 2003,
Psychoneuroendocrinology,
T Van Putten, and
P R May, and
S R Marder, and
L A Wittmann
October 2000,
Human psychopharmacology,
